New hope for down syndrome vision loss: light therapy trial launches

NCT ID NCT07135167

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a treatment called corneal crosslinking (CXL) for people with Down syndrome who have keratoconus, a condition where the cornea thins and bulges, blurring vision. The procedure uses vitamin B2 eye drops and ultraviolet light to strengthen the cornea. Researchers want to see if it can slow or stop vision loss. The study will enroll 225 people aged 8 and older and follow them for 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
riboflavin (vitamin B2) eye drops and ultraviolet (UVA) light
What this could lead to
If it works, this could offer a way to slow or stop vision loss from keratoconus in people with Down syndrome, helping them keep their sight longer.
What could go wrong
This is still experimental and not FDA-approved. The study is relatively small (225 people) and only follows participants for 6 months, so long-term benefits or risks are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DOWN SYNDROME (DS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Woolfson Eye Institute

    RECRUITING

    Atlanta, Georgia, 30328, United States

  • Woolfson Eye Institute

    RECRUITING

    Atlanta, Georgia, 30349, United States

  • Woolfson Eye Institute

    RECRUITING

    Canton, Georgia, 30114, United States

  • Woolfson Eye Institute

    RECRUITING

    Cumming, Georgia, 30041, United States

  • Woolfson Eye Institute

    RECRUITING

    Douglasville, Georgia, 30134, United States

  • Woolfson Eye Institute

    RECRUITING

    Lawrenceville, Georgia, 30043, United States

  • Woolfson Eye Institute

    RECRUITING

    Marietta, Georgia, 30066, United States

  • Woolfson Eye Institute

    RECRUITING

    Snellville, Georgia, 30078, United States

  • Woolfson Eye Institute

    RECRUITING

    Asheville, North Carolina, 28803, United States

  • Woolfson Eye Institute

    RECRUITING

    Chattanooga, Tennessee, 37421, United States

  • Woolfson Eye Institute

    RECRUITING

    Johnson City, Tennessee, 37615, United States

  • Woolfson Eye Institute

    RECRUITING

    Knoxville, Tennessee, 37922, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.